MALDI-ToF Rapid Microbial Identification
GMP/GLP compliant testing laboratory, Wickham Laboratories Ltd, announces the introduction of new MALDI-ToF, rapid microbial identification service.
Wickham Laboratories is pleased to announce the introduction of a new rapid microbial identification service, the MALDI Biotyper® or MALDI-ToF (Matrix Assisted Laser Desorption Ionisation-Time of Flight).
MALDI-ToF offers improved identification accuracy and compliance over traditional methods and reduces requirements for repeat testing. This rapid method can identify organisms to species level within minutes making same day identification a possibility.
Our prices for identification are competitive and may include volume discounts. For any organism not matching those present in our database, we will also provide an identification free of any additional charges. More information regarding this service is available on our website.
As a GMP/GLP compliant laboratory with over 50 years of experience, we are an established name in the fields of pharmaceutical and medical device contract testing, research and consultancy. We are routinely inspected by the MHRA, FDA and Home Office and maintain an audit ready facility at all times.
Conducting business with clients worldwide, the combined expertise of our laboratory technicians and managers enables us to be fully conversant with global regulatory expectations. For more information about Wickham Laboratories Limited and our services, please contact us at +44 (0)1329 226600 or mail@wickhamlabs.co.uk.
Contact Details :
Wickham Laboratories Ltd
Website: www.wickhamlabs.co.uk
E-mail: mail@wickhamlabs.co.uk
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
